top of page


Kinled Holding is a Partner in four dedicated life science investment companies based in Boston, Vienna, Monte Carlo, and Zurich, with combined Assets under Management of $250M, and two specific digital technology Funds based in Vienna and London with combined Assets under Management of €225M

Kinled Holding and the Aisher Family have long believed in fostering academic projects to become commercial businesses. We have proudly funded early stage businesses in Austria and Switzerland that originated in Universities such as Zürich, Bern, Fribourg, Geneva, Lausanne, Innsbruck, and Vienna and have a long-standing relationship with the Swiss Federal Institute of Technology and the University of Vienna. 


In the United States, we funded early stage businesses that originated in Universities from Boston, Cambridge, Harvard, Houston, Massachusetts Institute of Technology, Michigan, New York, Northeastern, San Diego, San Francisco, to Stanford. In Europe Kinled portfolio firms were created with technology from Universities such as Aix-Marseille, Amsterdam, Barcelona, Helsinki, Linköping, London, Paris, Pecs, and Utrecht


To learn more about some of successful exits, Click Here > 


Co-investment opportunities

Kinled welcomes sophisticated family-office investors to co-invest with us in academic/scientific projects and nascent technologies. This can be through direct equity participation in both regulated and unregulated investment vehicles such as our Vienna and Zürich-based accelerators Danube Labs and MountainLabs, or investing through our regulated Gibraltar-based fund CEBINA Bridge Capital.


Today all our investments are processed through three independently managed incubator/accelerators that Kinled is a founder shareholder in, and one EU regulated fund that we manage:

Danube Labs brings together CEBINA’s strength in scientific innovation and entrepreneurship, with Evotec’s industry-leading drug discovery and development expertise to accelerate academic life science research projects with a focus on Central and Eastern European Universities and Research Institutes.

Mountain Labs is Switzerland’s first full service search lab, start-up incubator and investment facilitator, sourcing new investment opportunities and bridging the gap between entrepreneurs and capital finance.

Cebina The Central European Biotech Incubator & Accelerator at the University of Vienna’s Campus Biotech, supports innovative biotechnology companies focused on inflammation, neurology and ageing. 

Cebina Bridge Capital is an EU AIFMD regulated fund whose objective is to provide absolute return to Participating Shareholders by investing in pharmaceutical drug discovery and biotech projects in Central and Eastern Europe.


Olipan, a professionally managed unregulated private investment company seeking to produce long-term returns through later-stage/pre-IPO life science opportunities, balanced by a conservative portfolio of residential real estate and public equities. Administration is effected by Landmark Management SAM in Monte Carlo and a group of experienced Austrian and English senior Swiss Bank Directors, Accountants, Professional Trust Directors, and Private Equity experts.

bottom of page